Most functions are unavailable without JavaScript. Please activate JavaScript and reload this page.
Please stand by while page is loading...
Cookies seem to be disabled in your browser, please check and activate them.
Cover
Our Mission
Share Trading Information 2009
Financial Key Figures/Pipeline
Contents Profile
2 Letter to Shareholders
3 Letter to Shareholders
4 Our Products
5 Catena®
6 Catena®
7 Catena®
8 Fipamezole
9 Omigapil / MC-4R Antagnonists
10 Our Inspiration
11 Staying in Touch
12 Staying in Touch
13 Staying in Touch
14 Main Achievements
15 MD&A
16 MD&A
17 Corporate Management
Contents Corporate Governance
CG-1
CG-2
CG-3
CG-4
CG-5
CG-6
CG-7
CG-8
CG-9
CG-10
CG-11
CG-12
CG-13
CG-14
CG-15
Contents Financial Report
F-1
F-2
F-3
F-4
F-5
F-6
F-7
F-8
F-9
F-10
F-11
F-12
F-13
F-14
F-15
F-16
F-17
F-18
F-19
F-20
F-21
F-22
F-23
F-24
F-25
F-26
F-27
F-28
F-29
F-30
F-31
F-32
F-33
F-34
F-35
F-36
F-37
F-38
F-39
F-40
F-41
F-42 Auditor report on consolidated financial statements
F-43 Auditor report on consolidated financial statements
Contents Statutory Financial Statements
F-45
F-46
F-47
F-48
F-49
F-50
F-51
F-52
F-53
F-54
F-55 Auditor report on financial statements
F-56 Auditor report on financial statements
Forward-looking Statement
Contacts
Imprint
Back
Profile
Our Mission
Letter to the Shareholders
Our Products
Our Inspiration
Main Achievements in 2009
Corporate Management
Financial Report
Corporate Governance
General Information
Group Structure and Shareholders (DCG 1)
Capital Structure (DCG 2)
Board of Directors (DCG 3)
Executive Management (DCG 4)
Compensation, Shareholdings and Loans (DCG 5)
Shareholder's Participation (DCG 6)
Changes of Control and Defense Measures (DCG 7)
Auditors (DCG 8)
Information Policy (DCG 9)
Consolidated Balance Sheet
Consolidated Income Statement
Consolidated Cash Flow Statement
Consolidated Statement of Changes in Equity
Notes to the Consolidated Financial Statements
Notes 1 to 10
1 General Information
2 Summary of Significant Accounting Policies
3 Critical Accounting Estimates, Assumptions and Judgments
4 Exchange Rates of Principal Currencies
5 Tangible Assets
6 Intangible Assets
7 Impairment Testing of Intangible Assets
8 Inventories
9 Trade and Other Receivables
10 Financial Assets and Liabilities – Short- and Long-term
Notes 11 to 20
11 Cash and Cash Equivalents
12 Share Capital
13 Deferred Taxes
14 Trade and Other Payables
15 Accrued Expenses
16 Short-term Provisions
17 Contingent Assets
18 Commitments and Contingent Liabilities
19 Stock Option Plans
20 Segment and Geographic Information
Notes 21 to 30
21 Gross Profit Breakdown
22 Other Operating Income
23 Operating Expenses by Function
24 Operating Expenses by Nature
25 Employee Expenses and Benefits
26 Financial Income/Expenses
27 Income Taxes
28 Earnings per Share
29 Related Party Transactions
30 Risk management Objectives and Policies
Notes 31 to 32
31 Effects from Restructuring
32 Events after the Balance-Sheet Date
Report of the Group Auditor
Balance Sheet
Income Statement
Notes to the Statutory Financial Statements
Proposals of the Board of Directors to the Annual Shareholder's Meeting
Report of the Statutory Auditor
